Top Page
Akeso, Inc.
(9926)
Akeso, Inc. (9926) vs. iShares MSCI Hong Kong ETF (EWH)
Akeso, Inc. Business Overview & Revenue Model
Akeso, Inc. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.12B | 4.53B | 837.66M | 225.63M | 0.00 |
| Gross Profit | 1.83B | 4.39B | 734.54M | 195.41M | -1.90M |
| EBITDA | -604.99M | 2.17B | -1.27B | -1.32B | -1.01B |
| Net Income | -514.51M | 2.03B | -1.17B | -1.07B | -1.04B |
Balance Sheet | |||||
| Total Assets | 12.75B | 9.18B | 5.50B | 4.81B | 3.86B |
| Cash, Cash Equivalents and Short-Term Investments | 7.32B | 2.40B | 2.29B | 2.65B | 2.80B |
| Total Debt | 3.95B | 2.99B | 1.88B | 859.42M | 198.99M |
| Total Liabilities | 6.00B | 4.66B | 2.95B | 1.53B | 405.73M |
| Stockholders Equity | 6.81B | 4.69B | 2.64B | 3.16B | 3.19B |
Cash Flow | |||||
| Free Cash Flow | -1.12B | 1.59B | -2.02B | -1.71B | -1.06B |
| Operating Cash Flow | -527.62M | 2.47B | -1.24B | -1.00B | -617.77M |
| Investing Cash Flow | -1.52B | -4.00B | -889.75M | -579.59M | -555.70M |
| Financing Cash Flow | 3.39B | 960.89M | 1.49B | 1.59B | 2.88B |
Akeso, Inc. Technical Analysis
Akeso, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | HK$88.01B | ― | -8.98% | ― | -54.66% | -123.11% | |
54 Neutral | €4.79B | 18.24 | -49.50% | 1.83% | 13.92% | -2.48% | |
| $11.94B | 49.05 | 6.14% | 1.53% | ― | ― | ||
| $17.34B | ― | -0.72% | ― | ― | ― | ||
| $12.96B | 25.09 | 8.17% | ― | ― | ― | ||
53 Neutral | HK$42.54B | ― | -56.68% | ― | 52.25% | 11.46% | |
51 Neutral | HK$35.20B | ― | -19.78% | ― | 25.96% | 39.58% |
Akeso, Inc. Corporate Events
Akeso, Inc. has announced an extraordinary general meeting to be held on June 30, 2025, in Zhongshan, Guangdong, China. The meeting will address resolutions to grant 3,000,000 share options and 2,000,000 RSUs to Dr. Xia under the company’s existing schemes, indicating a strategic move to incentivize key leadership and align their interests with the company’s growth objectives.
The most recent analyst rating on (HK:9926) stock is a Buy with a HK$58.97 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.
Akeso, Inc. has announced its upcoming annual general meeting, scheduled for June 30, 2025, in Zhongshan, Guangdong, China. The meeting will address several key resolutions, including the adoption of the company’s audited financial statements for 2024, the re-election of retiring directors, and the re-appointment of Ernst & Young as auditors. Additionally, the meeting will consider authorizing the board to manage the issuance of additional shares, which could impact the company’s capital structure and shareholder value.
The most recent analyst rating on (HK:9926) stock is a Buy with a HK$58.97 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.
Akeso, Inc. announced that China’s National Medical Products Administration has approved the supplemental New Drug Application for cadonilimab as a first-line treatment for cervical cancer. This approval marks a significant advancement in addressing the unmet needs for immune-based therapies in cervical cancer, offering a new treatment option for patients at all stages of the disease. The approval is based on successful results from the COMPASSION-16/AK104-303 study, which demonstrated improved progression-free and overall survival rates. This development positions Akeso as a leader in innovative cancer treatments, potentially impacting the company’s market presence and offering hope to stakeholders in the healthcare sector.
The most recent analyst rating on (HK:9926) stock is a Buy with a HK$58.97 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.
Akeso, Inc. announced the grant of 7,115,000 Share Options and Restricted Share Units (RSUs) to 114 grantees, including directors and employees, as part of its strategy to recognize contributions and motivate its workforce. The grant is considered fair and reasonable, with a 10-year validity period and a mixed vesting schedule to encourage long-term commitment and growth within the company.
The most recent analyst rating on (HK:9926) stock is a Buy with a HK$58.97 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.
Akeso, Inc. announced that its bi-specific antibody, ivonescimab, has received approval from the National Medical Products Administration for its use as a first-line treatment for non-small cell lung cancer (NSCLC) with positive PD-L1 expression. This approval is based on successful Phase III trial results demonstrating ivonescimab’s efficacy over pembrolizumab, marking a significant advancement in chemotherapy-free treatment options for NSCLC, and potentially enhancing Akeso’s position in the oncology market.
Akeso, Inc. announced that the U.S. FDA has approved its PD-1 monoclonal antibody, penpulimab-kcqx, for the treatment of advanced nasopharyngeal carcinoma (NPC) in two indications. This approval marks a significant milestone for Akeso, expanding the treatment options for NPC patients in the U.S. and highlighting the company’s commitment to addressing critical unmet medical needs. The approval is based on international clinical trials and follows previous designations by the FDA, underscoring the therapy’s potential impact on improving patient outcomes.
Akeso, Inc. announced that its PD-1/VEGF bispecific antibody, ivonescimab, combined with chemotherapy, has achieved positive results in a Phase III clinical trial for advanced squamous non-small cell lung cancer (sq-NSCLC). The trial, known as HARMONi-6, demonstrated statistically significant and clinically meaningful progression-free survival benefits compared to tislelizumab plus chemotherapy, with a favorable safety profile. These results position ivonescimab as a promising new treatment option for sq-NSCLC, potentially improving upon current standards of care and enhancing the clinical benefits of immunotherapy.
Akeso, Inc. announced that the National Medical Products Administration of China has approved the new drug application for Ebdarokimab, a treatment for moderate to severe plaque psoriasis. This approval marks a significant advancement for Akeso as it is their first Class 1 new drug approved for autoimmune diseases and the second non-oncology drug to receive marketing approval. Ebdarokimab has shown positive short-term and sustained long-term efficacy, significant improvement in patients’ quality of life, and a good safety profile. The drug is poised to address the growing needs of the psoriatic population in China, offering a cost-effective and convenient treatment option.
Akeso, Inc. announced a significant decrease in its financial performance for the year ended December 31, 2024, with revenue dropping by 53.08% compared to the previous year. Despite an increase in commercial sales, the company’s gross profit also fell by 58.23%, leading to a net loss of RMB501.1 million, primarily due to the absence of a substantial upfront payment received in 2023 from a collaboration with SUMMIT.